OvaScience Inc. (NASDAQ:OVAS) – Equities research analysts at Oppenheimer Holdings issued their FY2016 earnings per share (EPS) estimates for shares of OvaScience in a research note issued to investors on Monday. Oppenheimer Holdings analyst M. Ho anticipates that the brokerage will post earnings per share of ($2.48) for the year. Oppenheimer Holdings also issued estimates for OvaScience’s Q4 2016 earnings at ($0.58) EPS, FY2017 earnings at ($1.61) EPS, FY2018 earnings at ($0.86) EPS, FY2019 earnings at $0.32 EPS and FY2020 earnings at $1.56 EPS.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.08. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. OvaScience had a negative net margin of 11,642.67% and a negative return on equity of 62.66%. The company’s revenue for the quarter was down 73.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.66) earnings per share.

OVAS has been the subject of several other reports. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Wednesday, August 10th. JMP Securities restated a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. JPMorgan Chase & Co. decreased their price objective on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, August 5th. Finally, HC Wainwright restated a “buy” rating on shares of OvaScience in a report on Sunday, November 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $8.52.

Shares of OvaScience (NASDAQ:OVAS) opened at 3.55 on Thursday. OvaScience has a 12 month low of $3.39 and a 12 month high of $11.66. The company’s market cap is $126.41 billion. The firm has a 50-day moving average of $6.16 and a 200 day moving average of $6.39.

Several hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors increased its stake in shares of OvaScience by 31.8% in the second quarter. Nationwide Fund Advisors now owns 20,068 shares of the company’s stock valued at $105,000 after buying an additional 4,846 shares during the period. Citadel Advisors LLC purchased a new stake in shares of OvaScience during the second quarter valued at approximately $122,000. BlackRock Advisors LLC increased its stake in shares of OvaScience by 26.2% in the third quarter. BlackRock Advisors LLC now owns 17,001 shares of the company’s stock valued at $122,000 after buying an additional 3,529 shares during the period. ProShare Advisors LLC increased its stake in shares of OvaScience by 28.7% in the second quarter. ProShare Advisors LLC now owns 29,507 shares of the company’s stock valued at $154,000 after buying an additional 6,572 shares during the period. Finally, Northern Capital Management LLC increased its stake in shares of OvaScience by 61.0% in the second quarter. Northern Capital Management LLC now owns 30,340 shares of the company’s stock valued at $158,000 after buying an additional 11,500 shares during the period. 80.59% of the stock is currently owned by hedge funds and other institutional investors.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

5 Day Chart for NASDAQ:OVAS

Receive News & Stock Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related stocks with our FREE daily email newsletter.